US/EU Avandia decisions varied because of "toolbox", says FDA expert
This article was originally published in Scrip
Executive Summary
Pharmaceutical companies wanting to learn more on how different decisions are made by different regulatory agencies on their products (while using the same data) should take notice of one expert with the FDA. It seems it relies on the tools available to regulators.